Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sergio De Filippis

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Current Neuropharmacology|April 8, 2025
The Potential Influence of Associated Antidepressants on the Pharmacokinetic Profile of Esketamine in Patients Affected by Treatment-resistant DepressionMarika Alborghetti, Luana Lionetto, Ginevra Lombardozzi, et al.
Journal of Clinical Psychopharmacology|December 30, 2022
Two-Injection Start Regimen of Long-Acting Aripiprazole in 133 Patients With SchizophreniaAlessandro Cuomo, Eugenio Aguglia, Stefano Biagini, et al.
Expert Opinion on Drug Safety|February 18, 2016
Switching long acting antipsychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatristsAndrea Fagiolini, Emilia Alfonsi, Giovanni Amodeo, et al.
Human Psychopharmacology|May 17, 2018
Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydratePaolo Girardi, Antonio Del Casale, Chiara Rapinesi, et al.
Bipolar Disorders|January 13, 2023
Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depressionGiovanni Martinotti, Bernardo Dell'Osso, Giorgio Di Lorenzo, et al.
Psychiatry Research|August 27, 2025
Effectiveness of repeated Esketamine nasal spray administration on anhedonic symptoms in treatment-resistant bipolar and unipolar depression: A secondary analysis from the REAL-ESK study groupGiacomo d'Andrea, Clara Cavallotto, Mauro Pettorruso, et al.
Psychiatry Research|August 13, 2023
Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING)Mauro Pettorruso, Roberto Guidotti, Giacomo d'Andrea, et al.
Journal of Personalized Medicine|April 25, 2025
Patient Experience with Intranasal Esketamine in Treatment-Resistant Depression: Insights from a Multicentric Italian Study (REAL-ESKperience)Marco Di Nicola, Maria Pepe, Giacomo d'Andrea, et al.
Journal of Affective Disorders|September 27, 2022
Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study)Giovanni Martinotti, Antonio Vita, Andrea Fagiolini, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Current Neuropharmacology|April 8, 2025
The Potential Influence of Associated Antidepressants on the Pharmacokinetic Profile of Esketamine in Patients Affected by Treatment-resistant DepressionMarika Alborghetti, Luana Lionetto, Ginevra Lombardozzi, et al.
Journal of Clinical Psychopharmacology|December 30, 2022
Two-Injection Start Regimen of Long-Acting Aripiprazole in 133 Patients With SchizophreniaAlessandro Cuomo, Eugenio Aguglia, Stefano Biagini, et al.
Expert Opinion on Drug Safety|February 18, 2016
Switching long acting antipsychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatristsAndrea Fagiolini, Emilia Alfonsi, Giovanni Amodeo, et al.
Human Psychopharmacology|May 17, 2018
Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydratePaolo Girardi, Antonio Del Casale, Chiara Rapinesi, et al.
Bipolar Disorders|January 13, 2023
Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depressionGiovanni Martinotti, Bernardo Dell'Osso, Giorgio Di Lorenzo, et al.
Psychiatry Research|August 27, 2025
Effectiveness of repeated Esketamine nasal spray administration on anhedonic symptoms in treatment-resistant bipolar and unipolar depression: A secondary analysis from the REAL-ESK study groupGiacomo d'Andrea, Clara Cavallotto, Mauro Pettorruso, et al.
Psychiatry Research|August 13, 2023
Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING)Mauro Pettorruso, Roberto Guidotti, Giacomo d'Andrea, et al.
Journal of Personalized Medicine|April 25, 2025
Patient Experience with Intranasal Esketamine in Treatment-Resistant Depression: Insights from a Multicentric Italian Study (REAL-ESKperience)Marco Di Nicola, Maria Pepe, Giacomo d'Andrea, et al.
Journal of Affective Disorders|September 27, 2022
Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study)Giovanni Martinotti, Antonio Vita, Andrea Fagiolini, et al.
Pageof 7